MeiraGTx Holdings PLC
MGTX7.990USD
+0.660+9.00%
收盘 09/18, 16:00（美东）报价延迟15分钟
642.77M总市值
亏损市盈率 TTM
关于 MeiraGTx Holdings PLC 公司
MeiraGTx Holdings PLC 是一家垂直整合的临床阶段基因治疗公司。该公司专注于三个不同的未满足医疗需求领域：眼部疾病，包括遗传性视网膜疾病 (IRD) 以及大型退行性眼部疾病、严重形式的口干症和神经退行性疾病。其产品线包括 botaretigene sparoparvovec 或 bota-vec，用于治疗与视网膜色素变性 GTPase 调节基因或 XLRP-RPGR 突变相关的 X 连锁视网膜色素变性；AAV-hAQP1，用于治疗放射引起的 2/3 级口干症；AAV-hAQP1，用于治疗干燥综合征；AAV-GAD，用于治疗帕金森病；AAV-RPE65，用于治疗 RPE65 相关视网膜营养不良； AAV-CNGB3 和 AAV-CNGA3 用于治疗全色盲；AAV-AIPL1 用于治疗 LCA4，AAV-RDH12 用于治疗 RDH12 突变相关的视网膜营养不良。
公司简介
公司代码MGTX
公司名称MeiraGTx Holdings PLC
上市日期Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
员工数量381
证券类型Ordinary Share
年结日Jun 08
公司地址450 East 29Th Street
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10016
电话16468607985
网址https://meiragtx.com/
公司代码MGTX
上市日期Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
其他
47.68%
持股股东
持股股东
占比
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
其他
47.68%
股东类型
持股股东
占比
Hedge Fund
27.50%
Corporation
20.09%
Private Equity
15.69%
Venture Capital
8.26%
Investment Advisor
6.73%
Investment Advisor/Hedge Fund
5.43%
Individual Investor
4.27%
Research Firm
1.22%
Bank and Trust
0.06%
其他
10.75%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
12.58M
15.65%
--
--
Mar 31, 2025
Sanofi SA
12.20M
15.18%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.63M
7.01%
+600.00K
+11.92%
Mar 31, 2025
Prosight Capital
3.69M
4.59%
-699.29K
-15.93%
Mar 31, 2025
Rubric Capital Management LP
1.78M
2.21%
+1.78M
--
Mar 31, 2025
Adena Estate Inc.
3.27M
4.06%
+3.27M
--
Dec 31, 2023
683 Capital Management LLC
2.58M
3.2%
+160.00K
+6.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
3.39%
+87.69K
+3.32%
Mar 31, 2025
J. Goldman & Co., L.P.
1.16M
1.44%
+608.24K
+110.48%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.05%
iShares Biotechnology ETF
0.04%
Vanguard US Momentum Factor ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
查看更多
iShares Micro-Cap ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.06%
Goldman Sachs Innovate Equity ETF
占比0.05%
iShares Biotechnology ETF
占比0.04%
Vanguard US Momentum Factor ETF
占比0.03%
iShares Russell 2000 Growth ETF
占比0.02%
SPDR S&P International Small Cap ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
